Plus Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|
Revenue | $0 | $1,279 | $1,677 |
Gross Profit | -1,494 | 1,491 | |
EBITDA | -2,581 | -2,711 | -3,041 |
EBIT | -2,813 | -2,913 | -3,227 |
Net Income | -2,874 | -2,940 | -3,261 |
Net Change In Cash | 0 | 1,279 | 1,677 |
Free Cash Flow | -3,694 | -1,776 | -4,553 |
Cash | 1,223 | 4,912 | 2,901 |
Basic Shares | 7,855 | 10,742 | 4,321 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
Revenue | $4,913 | $224 | $0 |
Gross Profit | -4,777 | -488 | -66 |
EBITDA | -12,693 | -18,852 | -12,492 |
EBIT | -13,321 | -19,564 | -12,911 |
Net Income | -13,316 | -20,838 | -14,331 |
Net Change In Cash | 4,913 | 224 | 0 |
Free Cash Flow | -13,011 | -13,481 | -10,424 |
Cash | 8,554 | 18,120 | 18,400 |
Basic Shares | 3,140 | 1,750 | 805 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.49 |
2024-09-30 | -$0.37 |
2024-06-30 | -$0.56 |
2024-03-31 | -$0.75 |
